Arena Pharmaceuticals (ARNA) Given News Sentiment Rating of 0.09
Headlines about Arena Pharmaceuticals (NASDAQ:ARNA) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Arena Pharmaceuticals earned a daily sentiment score of 0.09 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.7076238989594 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern’s analysis:
- ETFs with exposure to Arena Pharmaceuticals, Inc. : September 22, 2017 (finance.yahoo.com)
- Zacks: Analysts Anticipate Arena Pharmaceuticals, Inc. (ARNA) Will Post Quarterly Sales of $4.39 Million (americanbankingnews.com)
- Consensus Buy Analysis: Arena Pharmaceuticals, Inc. (ARNA) – Street Observer (press release) (streetobserver.com)
- -$0.69 Earnings Per Share Expected for Arena Pharmaceuticals, Inc. (ARNA) This Quarter (americanbankingnews.com)
ARNA has been the topic of several recent analyst reports. Zacks Investment Research raised Arena Pharmaceuticals from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a report on Tuesday, July 4th. Leerink Swann increased their target price on Arena Pharmaceuticals from $47.00 to $53.00 and gave the company an “outperform” rating in a report on Tuesday, July 11th. Citigroup Inc. initiated coverage on Arena Pharmaceuticals in a report on Tuesday, June 27th. They issued a “buy” rating and a $23.00 target price on the stock. BidaskClub lowered Arena Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Finally, JMP Securities raised Arena Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $27.00 target price on the stock in a report on Friday, July 7th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the stock. Arena Pharmaceuticals currently has an average rating of “Buy” and an average target price of $36.00.
Arena Pharmaceuticals (NASDAQ:ARNA) opened at 25.09 on Friday. The stock’s market cap is $984.03 million. The firm’s 50 day moving average price is $22.59 and its 200 day moving average price is $17.41. Arena Pharmaceuticals has a one year low of $11.30 and a one year high of $27.86.
Arena Pharmaceuticals (NASDAQ:ARNA) last issued its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.03). Arena Pharmaceuticals had a negative return on equity of 49.87% and a negative net margin of 16.27%. The firm had revenue of $6.49 million during the quarter, compared to analyst estimates of $5.58 million. During the same quarter in the prior year, the firm earned ($1.10) EPS. The business’s quarterly revenue was down 31.8% compared to the same quarter last year. Equities analysts forecast that Arena Pharmaceuticals will post ($2.94) earnings per share for the current year.
WARNING: This piece was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/24/arena-pharmaceuticals-arna-given-news-sentiment-rating-of-0-09.html.
Arena Pharmaceuticals Company Profile
Arena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn’s disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH).
Receive News & Stock Ratings for Arena Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arena Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.